AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.
Back to search results

Diabetes model derived from embryonic and pluripotent stem cells

Summary
Rudy Leibel, M.D.
Technology Benefits
Enables generation of therapeutic cells from directly from a patient.Provides a closely related model of the disease as the generated cells are derived directly from the patients themselves.Patients with rare disease mutations of diabetes may benefit from this technology because the efficacy of potential treatments may be tested first using this technology before being applied directly.Patent Information:Patent Pending
Technology Application
Method for generating beta cells for diagnostic and therapeutic applications.Efficient and reliable platform for studying cellular effects of diabetes mutations from the patient carrying the disease. In vitro testing platform for diabetes treatments.Protocols could be modified to derive other cell lines (i.e. hepatic, adipocyte, muscle, etc).
Detailed Technology Description
Rudy Leibel, M.D.
*Abstract
None
*Inquiry
Ron KatzColumbia Technology VenturesTel: (212) 854-8444Email: TechTransfer@columbia.edu
*IR
cu12149
*Principal Investigator
Country/Region
USA

For more information, please click Here
Mobile Device